The first generation of immunotherapies,
including immune checkpoint inhibitors and cancer vaccines, have been limited by the proportion of patients who benefit, and by the depth and duration of response in those that do.
Not exact matches
The cancer cells» defense strategy can be overcome by
immune checkpoint inhibitor agents,
including anti-PD-1 / PD - L1 antibodies, several kinds of which have received fast - track approval from the U.S. Food and Drug Administration (FDA).
R&D Systems offers a wide range of reagents and kits designed to study the
immune checkpoint,
including blocking antibodies, proteins, assays, and more.
Through strategic partnerships with industry and nonprofit organizations, we gain access to a portfolio of priority drugs for testing within our expert focus groups,
including checkpoint inhibitors, therapeutic vaccines, innate
immune stimulants, targeted therapies, and many other promising treatments and technologies with high therapeutic potential.
These
include therapies that target other
immune checkpoint receptors such as Tim3 and Lag3 (2) or other inhibitory receptors
including the adenosine 2A receptor, PGE2 receptor, and TGF - β receptor complex (7, 8).
Their work encompasses several strategies,
including: developing FL - HCC animal models to characterize tumor -
immune interactions, exploring if a mutated protein associated with FL - HCC could be targeted by immunotherapy, identifying
immune checkpoints that could potentially serve as targets for immunotherapy as well as biomarkers for analyzing patients, and evaluating the effectiveness of immunotherapy strategies against FL - HCC patient samples in the lab.
The final aim is improving therapeutic effect and defining rationalized drug combinations with
immune checkpoints and proprietary molecules developed by collaborators,
including novel immunomodulatory approaches generated at our unit.